Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

391 articles about Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

• Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation

  11/22/2021

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients.

• Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates

  11/10/2021

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the third quarter ended September 30, 2021 and provided key business updates.

• Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime PatentAnticipated New Patent Will Provide Intellectual Property Protection Until Late 2039

  10/25/2021

  Windtree Therapeutics, Inc. today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of new patent claims for istaroxime administration.

• Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock Tuesday, October 19th @ 8:00 am Eastern Time

  10/14/2021

  Windtree Therapeutics, Inc. today announced that on Tuesday, October 19, 2021 at 8:00 am Eastern Time it will host a Key Opinion Leader (KOL) webinar on istaroxime for the treatment of acute heart failure and the upcoming data in early cardiogenic shock.

• Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results

  10/12/2021

  Windtree Therapeutics, Inc. today announced the results of a US physician survey and an assessment of worldwide total market value for cardiogenic shock.

• Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

  9/16/2021

  Windtree Therapeutics, Inc. today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.

• 

  BioSpace Movers & Shakers, Aug. 6

  8/6/2021

  Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.

• Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

  8/5/2021

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

• Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management

  8/2/2021

  Windtree Therapeutics, Inc. announced the appointment of Randall White, Ph.D., as Vice President, Clinical Program Management, reporting to Steve Simonson, M.D., Senior Vice President and Chief Medical Officer of Windtree.

• Windtree to Present at Access to Giving Virtual Investor Conference

  7/8/2021

  Windtree Therapeutics, Inc. today announced that Craig Fraser, President and Chief Executive Officer, will present at the Access to Giving Virtual Investor conference, which is being held virtually July 13–15, 2021.

• Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

  7/7/2021

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:

• 

  BioSpace Movers & Shakers, July 2

  7/2/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel

  7/1/2021

  Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced the appointment of Diane Carman, Esq. as Senior Vice President and General Counsel, reporting to Craig Fraser, President and Chief Executive Officer.

• 

  How the U.S. Military Primed Windtree CEO Craig Fraser for C-Suite Success

  6/30/2021

  Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.

• Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

  5/13/2021

   Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.

• Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

  4/19/2021

  Windtree Therapeutics, Inc. today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT).

• Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates

  3/29/2021

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates.

• Windtree Therapeutics Announces Closing of $30.0 Million Public Offering

  3/25/2021

   Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the closing of its previously announced public offering of 9,230,500 shares of its common stock

• Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering

  3/23/2021

  Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the pricing of its previously announced public offering of 9,230,500 shares of our common stock

• Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

  3/22/2021

  Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has commenced an underwritten public offering of its shares of common stock and warrants to purchase shares of common stock